Clinical Trials

View All Clinical Trials

The results of your search are listed below. To view the details of a trial or study, click on the "see details >>" link. Or start a new search.

No search term entered. 222 results shown below.

Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma

[Complete title: A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Non-Myeloablative Allogeneic Stem Cell Transplantation for Patients with Relapsed or Refractory Lymphoma - A Multi-Center Trial]
Principal Investigator: David Maloney, MD, PhD
Study Number: 1409.00
Phase: I/II

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

[Complete title: Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected with HIV-1 Using a Non-Marrow Ablative Conditioning Regimen Containing TBI in Combination with Post-Transplant Immunosuppression with Cyclosporine and Mycophenolate Mofetil]
Principal Investigator: Ann Woolfrey, MD
Study Number: 1410.00
Phase: I

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

[Complete title: A Phase II Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody with Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients with Advanced AML or High Risk Myelodysplastic Syndrome]
Principal Investigator: John Pagel, MD, PhD
Study Number: 1809.00
Phase: II

Fludarabine, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

[Complete title: Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 1840.00
Phase: II

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed By a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

[Complete title: Hematopoietic Cell Transplantation for Treatment of Patients with Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-dose TBI and Fludarabine With or Without Campath®]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2007.00
Phase: II

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant, Cyclophosphamide, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Immunodeficiency or Noncancerous Inherited Disorders

[Complete title: HLA-haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning With Low-dose Cyclophosphamide, TBI and Fludarabine; Postgrafting Immunosuppression Will Consist of a Single Low Dose of Cyclophosphamide, MMF and Tacrolimus]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2032.00
Phase: II

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

[Complete title: Low-dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders -- A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2056.00
Phase: II

Nonmyeloablative transplant for severe systemic sclerosis

[Complete title: Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis]
Principal Investigator: George Georges, MD
Study Number: 2067.00
Phase: I/II

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

[Complete title: Tandem Autologous HCT / Nonmyeloablative Allogeneic HCT from HLA-Matched Related and Unrelated Donors Followed by Bortezomib Maintenance Therapy for Patients with High-Risk Multiple Myeloma]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2070.00
Phase: II

Gene Therapy for Fanconi Anemia

[Complete title: Gene Transfer for Patients with Fanconi Anemia Complementation Group A (FANCA)]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 2097.00
Phase: I

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

[Complete title: A Multi-center Phase II Study of Selective Depletion of CD45RA+ T cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD]
Principal Investigator: Marie Bleakley, MD
Study Number: 2222.00
Phase: II

Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

[Complete title: Allogeneic Hematopoietic Cell Transplantation for Patients with Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2256.00
Phase: II

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma

[Complete title: Bortezomib and Vorinostat as Maintenance Therapy after Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 2292.00
Phase: II

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

[Complete title: Hematopoietic Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2309.00
Phase: I

Montelukast to Treat Bronchiolitis Obliterans

[Complete title: Multi-Institutional Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic Stem Cell Transplantation in Children and Adults]
Principal Investigator: Guang-Shing Cheng
Study Number: 2317.00
Phase: II

Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

[Complete title: A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Cell Transplantation]
Principal Investigator: Mary Flowers, MD
Study Number: 2343.00
Phase: II

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

[Complete title: A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (anti-CD45) Antibody followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 2361.00
Phase: I

Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)

[Complete title: A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus plus Prednisone and Sirolimus/Calcineurin Inhibitor plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease]
Principal Investigator: Paul Carpenter, MD
Study Number: 2375.00
Phase: II/III

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

[Complete title: A phase II trial of high-dose 90Y-Ibritumomab tiuxetan (anti-CD20) followed by fludarabine and low-dose total body irradiation and HLA-matched allogeneic hematopoietic transplantation for patients with relapsed or refractory aggressive B-cell lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 2398.00
Phase: II

Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study of Optimally Dosed Clofarabine in Combination with Low-Dose TBI to Decrease Relapse Rates after Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients with AML]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2430.00
Phase: II

Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy

[Complete title: Phase 2 Study of Early Discharge and Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML]
Principal Investigator: Roland Walter, MD
Study Number: 2449.00
Phase: II

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

[Complete title: A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2450.00
Phase: I

Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

[Complete title: A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (anti-CD45) Antibody followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2468.00
Phase: I

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

[Complete title: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)]
Principal Investigator: Bill Bensinger, MD
Study Number: 2477.00
Phase: III

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

[Complete title: AMC PROTOCOL #075: A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin’s Lymphoma. A Trial of the AIDS Malignancy Consortium (AMC)]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2483.00
Phase: I/II

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

[Complete title: Phase I/II study of adoptive immunotherapy with virus specific CD8+ T cells that have been transduced to express a WT1-specific T cell receptor for patients with high risk or relapsed AML, MDS, or CML]
Principal Investigator: Merav Bar, MD
Study Number: 2498.00
Phase: I/II

Treosulfan and Fludarabine Phosphate With or Without Total Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome

[Complete title: A Randomized Phase II Multi-Center Study of Treosulfan, Fludarabine and Low-Dose TBI as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome (MDS)]
Principal Investigator: Joachim Deeg, MD
Study Number: 2524.00
Phase: II

Autologous T Cells, Low-Dose Recombinant Interferon Gamma, Cyclophosphamide, and Low-Dose Aldesleukin in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

[Complete title: A Phase I Study To Determine the Feasibility of Using Autologous NY-ESO-1 Specific CD8+ T Cells For the Treatment of Patients With Advanced Myxoid/ Round Cell Liposarcoma and Synovial Sarcoma]
Principal Investigator: Seth Pollack
Study Number: 2537.00
Phase: I

Crohn's Allogeneic Transplant Study (CATS)

[Complete title: Allogeneic Hematopoietic Cell Transplantation for Patients with Treatment-Refractory Crohn’s Disease: A Phase 2 Study]
Principal Investigator: George McDonald, MD
Study Number: 2551.00
Phase: II

Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

[Complete title: Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Induction Chemotherapy (FLAG) in Patients with Relapsed/Refractory AML]
Principal Investigator: Ann Dahlberg
Study Number: 2584.00
Phase: Pilot

Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma

[Complete title: Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma]
Principal Investigator: Aude Chapuis, MD
Study Number: 2586.00
Phase: I

Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

[Complete title: A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction with Busulfan, Cyclophosphamide and Fludarabine]
Principal Investigator: K.Scott Baker
Study Number: 2598.00
Phase: II

Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

[Complete title: Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off–the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2603.00
Phase: II

Internet and Social-Media Program for Improving Quality of Life in Long-Term Cancer Survivors Who Underwent Stem Cell Transplant

[Complete title: INSPIRE for Survivorship after Transplant: A Multicenter Randomized Controlled Trial of an Internet and Social-media Program for Long-term Hematopoietic Cell Transplantation Survivors]
Principal Investigator: Karen Syrjala, PhD
Study Number: 2605.00
Phase: III

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

[Complete title: A Phase II Study Of Weekly Maintenance Bortezomib And Rituximab In Mantle Cell Lymphoma S/P Autologous Hematopoietic Cell Transplantation]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 2620.00
Phase: II

Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality

[Complete title: Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality]
Principal Investigator: Roland Walter, MD
Study Number: 2642.00
Phase: Pilot

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

[Complete title: Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion with Cyclophosphamide and Fludarabine For Patients With Metastatic Melanoma]
Principal Investigator: Sylvia Lee, MD
Study Number: 2643.00
Phase: II

Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

[Complete title: Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase I/II Study]
Principal Investigator: Roland Walter, MD
Study Number: 2652.00
Phase: I/II

Palliative Care Support for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant

[Complete title: Feasibility of Implementing Pre-Transplant Evaluation by the Supportive Care Team for Patients Undergoing Hematopoietic Cell Transplantation for Hematological Malignancies]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 2659.00
Phase: Pilot

Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children

[Complete title: A Phase II Study of Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children]
Principal Investigator: Marie Bleakley, MD
Study Number: 2660.00
Phase: II

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)

[Complete title: Initial cytoreductive therapy for myelodysplastic syndrome prior to allogeneic hematopoietic cell transplantation (the ICT-HCT Study)]
Principal Investigator: Bart Scott, MD
Study Number: 2661.00
Phase: II

Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

[Complete title: Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML)]
Principal Investigator: Mazyar Shadman
Study Number: 2674.00
Phase: II

Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma

[Complete title: A Pilot Study To Test Whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients with Synovial Sarcoma and Myxoid/ Round Cell Liposarcoma]
Principal Investigator: Seth Pollack
Study Number: 2705.00
Phase: Pilot

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer

[Complete title: Combined Targeted Therapies for Triple Negative Advanced Breast Cancer – A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy with Bevacizumab and Erlotinib]
Principal Investigator: Jennifer Specht, MD
Study Number: 6628
Phase: II

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

[Complete title: A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)]
Principal Investigator: Marc Chamberlain, MD
Study Number: 6803
Phase: II

Molecular Correlates of Sensitivity and Resistance to Therapy in Prostate Cancer

[Complete title: Molecular correlates of sensitivity and resistance to therapy in prostate cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 6932
Phase: NA

High-dose Methotrexate and Liposomal Cytarabine in Treating Patients With CNS Metastases From Breast Cancer

[Complete title: Phase II Study of the Combination of High-dose Methotrexate and Intrathecal Liposomal Cytarabine in Patients with Leptomeningeal Metastases with or without Parenchymal Brain Involvement]
Principal Investigator: Maciej Mrugala, MD, PhD
Study Number: 6954
Phase: II

A Phase 1 Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

[Complete title: A Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women (Novel Markers Trial)]
Principal Investigator: Nicole Urban, Sc.D., ScD
Study Number: 6973
Phase: I

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

[Complete title: A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-Over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung]
Principal Investigator: Robin Jones
Study Number: 7008
Phase: II

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

[Complete title: Multicenter Selective Lymphadenectomy Trial II (MSLT II): A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node]
Principal Investigator: David Byrd, MD
Study Number: 7108
Phase: III

Vaccine Therapy in Treating Patients With Stage III-IV Ovarian Cancer

[Complete title: A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients with Advanced Ovarian Cancer]
Principal Investigator: Nora Disis, MD
Study Number: 7396
Phase: I

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

[Complete title: Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN)]
Principal Investigator: Laura Chow
Study Number: 7406
Phase: I

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Patients With Stage II-IV HER2-Positive Breast Cancer

[Complete title: Phase I-II Study of HER2 Vaccination with poly(I)* poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients]
Principal Investigator: Lupe Salazar, MD
Study Number: 7425
Phase: I/II

Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

[Complete title: The Effect of Antiangiogenic Therapy with Pazopanib Prior to Preoperative Chemotherapy for Subjects with Extremity Soft Tissue Sarcomas: A Randomized Study to Evaluate Response by Imaging]
Principal Investigator: Robin Jones
Study Number: 7487
Phase: Pilot

Human Papillomavirus (HPV) or Pap Examination (HOPE) Study

[Complete title: Cytology vs. at home HPV screening for detection of CIN 2,3,CIS]
Principal Investigator: Nancy Kiviat, MD
Study Number: 7489
Phase: NA

Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

[Complete title: A Phase I dose-intensification study using radiation therapy and concurrent cisplatin and etoposide for patients with inoperable non-small cell lung cancer]
Principal Investigator: Shilpen Patel, MD
Study Number: 7506
Phase: I

I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

[Complete title: I-SPY2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis 2)]
Principal Investigator: Larissa Korde
Study Number: 7518
Phase: II

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

[Complete title: Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy with [18F]fluorothymidine (FLT) PET]
Principal Investigator: Hannah Linden, MD
Study Number: 7536
Phase: NA

BKM120 in Metastatic Castration-resistant Prostate Cancer

[Complete title: A Phase II Study of BKM120 in Men with Metastatic Castration-Resistant Prostate Cancer BKM120 Investigator-Initiated Protocol]
Principal Investigator: Evan Yu, MD
Study Number: 7553
Phase: II

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

[Complete title: A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Currently Receiving and Progressing on Docetaxel Therapy]
Principal Investigator: Evan Yu, MD
Study Number: 7563
Phase: II

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

[Complete title: Quantitative Dynamic PET and MRI and Breast Cancer Therapy]
Principal Investigator: Jennifer Specht, MD
Study Number: 7587
Phase: NA

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

[Complete title: Open Label Pharmacodynamic Study of Abiraterone Acetate in the Treatment of Metastatic, Castration Resistant Prostate Cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 7639
Phase: II

Capecitabine and Celecoxib With or Without Radiation Therapy in Treating Patients With Colorectal Cancer Previously Treated With Fluorouracil

[Complete title: A Phase II Trial of Maintenance ADAPT Therapy with Capecitabine and Celecoxib in Patients with Metastatic Colorectal Cancer]
Principal Investigator: Edward Lin, MD
Study Number: 7707
Phase: II

Memory and Thinking Skills Workshop in Improving Cognitive Rehabilitation in Gynecologic and Breast Cancer Survivors

[Complete title: Behavioral and Neural Indices of Cognitive Rehabilitation in Women's Cancer: A Pilot Study]
Principal Investigator: Heidi Gray, MD
Study Number: 7750
Phase: Pilot

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

[Complete title: A Phase II Study of Weekly ABRAXANE® for Patients with Advanced NSCLC with EGFR Mutations or with Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front-Line Therapy with EGFR Tyrosine Kinase Inhibitors]
Principal Investigator: Christina Baik
Study Number: 7755
Phase: II

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

[Complete title: A Phase II Study of Carboplatin, Nab-Paclitaxel and Cetuximab for Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 7797
Phase: II

Brentuximab Vedotin in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

[Complete title: A Pilot Study of Weekly Brentuximab Vedotin in Patients with CD30+ Malignancies Refractory to Every > = 3 Week Brentuximab Vedotin]
Principal Investigator: Ajay Gopal, MD
Study Number: 7808
Phase: Pilot

Cabozantinib in Treating Men With Hormone-Resistant Prostate Cancer

[Complete title: A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 7819
Phase: Pilot

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

[Complete title: A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B]
Principal Investigator: Hannah Linden, MD
Study Number: 7841
Phase: Pilot

Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer

[Complete title: Degarelix Acetate Prior to Radiation Therapy]
Principal Investigator: Robert Montgomery, MD
Study Number: 7846
Phase: Pilot

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

[Complete title: A Randomized Gene Fusion Stratified Phase 2 Trial Of Abiraterone With Or Without ABT-888 For Patients With Metastatic Castration-Resistant Prostate Cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 7847
Phase: II

Vaccine Therapy and Trastuzumab With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer

[Complete title: Phase I/II Randomized Study of Combination Immunotherapy With or Without Polysaccharide Krestin (PSK®) Concurrently with a HER2 ICD Peptide-Based Vaccine and Trastuzumab in Patients with Stage IV Breast Cancer]
Principal Investigator: Lupe Salazar, MD
Study Number: 7866
Phase: I/II

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

[Complete title: Phase II Study to Evaluate the Development of HER2/neu (HER2)-Specific Memory T Cells After HER2 Peptide-Based Vaccination in Patients with Advanced Stage HER2+ Breast Cancer]
Principal Investigator: Lupe Salazar, MD
Study Number: 7905
Phase: II

Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors (LDTam)

[Complete title: Low-dose Tamoxifen For Radiation-Induced Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial]
Principal Investigator: Larissa Korde
Study Number: 7908
Phase: II

Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

[Complete title: Feasibility of Outpatient Induction Chemotherapy for Adult Patients with Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 7910
Phase: Pilot

revention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer

[Complete title: Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer]
Principal Investigator: Larissa Korde
Study Number: 7952
Phase: NA

Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

[Complete title: Phase I/II Adaptive Randomized Trial of Bevacizumab versus Bevacizumab plus Vorinostat in Adults with Recurrent Glioblastoma]
Principal Investigator: Marc Chamberlain, MD
Study Number: 7994
Phase: I/II

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

[Complete title: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 8003
Phase: NA

RTOG 1205: Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Principal Investigator: George Laramore, MD, PhD
Study Number: 8024
Phase: II

Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

[Complete title: A Phase 1-2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients with Bladder Cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 8027
Phase: I/II

A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved therapy with Sipuleucel-T (Provenge®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer (mCRPC)
Principal Investigator: Evan Yu, MD
Study Number: 8037A
Phase: II

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

[Complete title: A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients with Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 8040
Phase: II

Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients

[Complete title: Psychoeducation for Spouses/Partners of Women with Breast Cancer]
Principal Investigator: Frances Lewis
Study Number: 8061
Phase: NA

Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer

[Complete title: Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC)]
Principal Investigator: Hannah Linden, MD
Study Number: 8093
Phase: II

Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Cisplatin

[Complete title: Intensive Trial of OMics in Cancer (ITOMIC) 001- Intensive Longitudinal Monitoring in Patients with Triple Negative Breast Cancer]
Principal Investigator: Tony Blau, MD
Study Number: 8132
Phase: NA

SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy

[Complete title: Pulmonary Functional Imaging for Radiation Treatment Planning for Lung Cancer]
Principal Investigator: Jing Zeng
Study Number: 8180
Phase: Pilot

DCE-MRI and DWI for Detection and Diagnosis of Breast Cancer

[Complete title: ACRIN 6702: A Multi-center Study Evaluating the Utility of Diffusion Weighted Imaging for Detection and Diagnosis of Breast Cancer]
Principal Investigator: Habib Rahbar
Study Number: 9049
Phase: NA

Efficacy of Carboplatin Administered Concomitantly with Radiation and Isoretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Principal Investigator: James Olson, MD, PhD
Study Number: ACNS0332
Phase: III

European Ewing Tumor Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G. 99)
Principal Investigator: Doug Hawkins, MD
Study Number: AEWS0331
Phase: III

Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)
Principal Investigator: Doug Hawkins, MD
Study Number: ARST0531
Phase: III

International Collaborative Treatment Protocol For Infants Under One Year With Acute Lymphoblastic Or Biphenotypic Leukemia
Principal Investigator: Blythe Thomson, MD
Study Number: CHMC-2006
Phase: III

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0724/ RTOG 0724
Phase: III

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

[Complete title: Pentostatin and Donor Lymphocyte Infusion for Low Donor T-Cell Chimerism After Hematopoietic Cell Transplantation - A Multicenter Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 1825.00
Phase: II

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

[Complete title: Transplantation of Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2010.00
Phase: II

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia or High-Risk Myelodysplastic Syndrome

[Complete title: Hematopoietic Bone Marrow Transplantation for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After Transplantation]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2186.00
Phase: II

Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD after Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation – A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2206.00
Phase: II

Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer

[Complete title: Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution After Myeloablative Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected with HIV]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2212.00
Phase: II

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

[Complete title: A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2230.00
Phase: I/II

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin

[Complete title: A Study Evaluating Escalating Doses of 131I-BC8 (anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 2238.00
Phase: I

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

[Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen]
Principal Investigator: Rachel Salit
Study Number: 2239.00
Phase: II

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

[Complete title: Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT using Related, HLA-Haploidentical Donors for Patients with High-Risk lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2241.00
Phase: II

Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy

[Complete title: High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients with Autoimmune Neurologic Diseases]
Principal Investigator: George Georges, MD
Study Number: 2260.00
Phase: II

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Donor Umbilical Cord Blood Transplant

[Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Treosulfan Based Preparative Regimen]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2275.00
Phase: II

Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.

[Complete title: Phase I Feasibility Study of Clofarabine and Low Dose Total Body Irradiation (TBI) as a Non-myeloablative Preparative Regimen for Stem Cell Transplantation (SCT) for Hematological Malignancies: a Multi-Center Study]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2284.00
Phase: I

Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

[Complete title: Longitudinal Study of Immune Mediated Disorders after Allogeneic HCT]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 2342.00
Phase: NA

Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant

[Complete title: Targeted Therapy of Bronchiolitis Obliterans Syndrome (BOS)]
Principal Investigator: Guang-Shing Cheng
Study Number: 2367.00
Phase: II

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

[Complete title: Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source]
Principal Investigator: Rachel Salit
Study Number: 2372.00
Phase: II

Computer-Guided Glucose Management Systems in Treating Patients With Hyperglycemia Who Have Undergone Blood and Bone Marrow Transplant

[Complete title: Use of Computer-Guided Glucose Management Systems for Patients Undergoing Blood and Marrow Transplants (BMT)]
Principal Investigator: Merav Bar, MD
Study Number: 2425.00
Phase: Pilot

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2448.00
Phase: III

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

[Complete title: A Phase I/II Study of Cellular Immunotherapy with Donor Central Memory-Derived Virus-Specific CD8+ T-Cells Engineered to Target CD19 for CD19+ Malignancies after Allogeneic Hematopoietic Stem Cell Transplant]
Principal Investigator: Cameron Turtle, PhD, MBBS
Study Number: 2494.00
Phase: I/II

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

[Complete title: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2531.00
Phase: NA

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

[Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Myeloablative Hematopoietic Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2545.00
Phase: II

Donor Atorvastatin -Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplantation

[Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Nonmyeloablative Hematopoietic Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2546.00
Phase: II

Alpha 1 Anti-Trypsin in Treating Patients With Acute Graft-Versus-Host Disease

[Complete title: Treatment of steroid non-responsive acute GVHD with alpha 1 anti-trypsin (AAT). A phase I/II study.]
Principal Investigator: Joachim Deeg, MD
Study Number: 2571.00
Phase: I/II

Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)

[Complete title: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies]
Principal Investigator: Rachel Salit
Study Number: 2580.00
Phase: III

Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease

[Complete title: A Single-Center Phase II Study of Bandage Lenses for Ocular Graft-versus- Host Disease after Allergenic Hematopoietic Cell Transplantation.]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 2617.00
Phase: II

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

[Complete title: Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma with Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor]
Principal Investigator: David Maloney, MD, PhD
Study Number: 2639.00
Phase: I/II

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

[Complete title: A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (anti-CD45) Antibody followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 2728.00
Phase: I/II

Cognitive Rehabilitation in Cancer Survivors: A Pilot Study
Principal Investigator: Monique Cherrier, PhD
Study Number: 7279
Phase: NA

Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer

[Complete title: Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 7674
Phase: II

Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas

[Complete title: A Phase I/II Trial of Bendamustine/Treanda, Rituximab, Etoposide and Carboplatin for Patients with Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas (TREC)]
Principal Investigator: Ajay Gopal, MD
Study Number: PSOC 2502
Phase: I/II

A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
Principal Investigator: George Laramore, MD, PhD
Study Number: 6864
Phase: III

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally - Advanced Resected Head and Neck Cancer
Principal Investigator: George Laramore, MD, PhD
Study Number: 7428
Phase: III

A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer
Principal Investigator: George Laramore, MD, PhD
Study Number: 7585
Phase: III

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Head and Neck Cancer

[Complete title: A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer]
Principal Investigator: John Thompson, MD
Study Number: 7637a
Phase: I

RTOG 0926 A Phase II Protocol For Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment By Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging.
Principal Investigator: George Laramore, MD, PhD
Study Number: 7684
Phase: II

RTOG 0834: Phase III Trial On Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The CATNON Intergroup Trial
Principal Investigator: George Laramore, MD, PhD
Study Number: 7880
Phase: III

RTOG 1175/CALGB 80803: Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Principal Investigator: George Laramore, MD, PhD
Study Number: 8076
Phase: II

Intensified Methotrexate, Nelarabine (Compound 506U78 IND # 52611) and Augmented BFM Therapy in Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
Principal Investigator: Blythe Thomson, MD
Study Number: AALL0434
Phase: III

A Study of Neurocognitive Function in Children Treated for ALL. A Group-wide, Non-therapeutic Companion Study to AALL0232 and AALL0434
Principal Investigator: Doug Hawkins, MD
Study Number: AALL06N1
Phase: NA

A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
Principal Investigator: J. Russell Geyer, MD
Study Number: ACNS0331
Phase: III

Phase III, Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High-Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Principal Investigator: Julie Park, MD
Study Number: ANBL0032
Phase: III

Treatment of Adrenocortical Tumors with Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy
Principal Investigator: Doug Hawkins, MD
Study Number: ARAR0332
Phase: III

Treatment of High Risk Renal Tumors; A Groupwide Phase II Study.
Principal Investigator: Doug Hawkins, MD
Study Number: AREN0321
Phase: II

Treatment for Very Low, Low, and Standard Risk Favorable Histology Wilms Tumor. A Groupwide Phase III Study
Principal Investigator: Doug Hawkins, MD
Study Number: AREN0532
Phase: III

Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Principal Investigator: Doug Hawkins, MD
Study Number: AREN0533
Phase: III

Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)
Principal Investigator: Doug Hawkins, MD
Study Number: ARST0332
Phase: III

A Phase I Study of Temozolomide, oral Irinotecan and Vincristine for Children with Refractory Solid Tumors
Principal Investigator: Julie Park, MD
Study Number: COG ADVL0414
Phase: I

A Single Arm Trial of Systemic and Subtenon Chemotherapy for Group C/D Intraocular Retinoblastoma
Principal Investigator: Doug Hawkins, MD
Study Number: COG ARET0231
Phase: III

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab (NSC#704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0213
Phase: II/III

A Randomized Phase III Trial of Cisplatin and Tumor Volume Directional Irradiation Followed By Carboplatin and Paclitaxel Vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0258
Phase: III

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

[Complete title: A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer]
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0260
Phase: II

Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder in Patients with Recurrent or Resistant Neuroblastoma (IND # 68254)
Principal Investigator: Julie Park, MD
Study Number: NANT 2004-04
Phase: I

Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) with Autologous Stem Cell Support for Resistant/Recurrent High-Risk Neuroblastoma (IND #69,112)
Principal Investigator: Julie Park, MD
Study Number: NANT 99-02
Phase: I

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy
Principal Investigator: Tanya Wahl, MD
Study Number: NSABP B-43
Phase: III

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Principal Investigator: Tanya Wahl, MD
Study Number: NSABP B-47
Phase: III

A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment

[Complete title: A Multicenter, Open-label Single-arm Study of YONDELIS® (trabectedin) for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment]
Principal Investigator: Robin Jones
Study Number: 20051530
Phase: III

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

[Complete title: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM]
Principal Investigator: Maciej Mrugala, MD, PhD
Study Number: 20090487
Phase: III

A Study in Second Line Metastatic Colorectal Cancer

[Complete title: A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine]
Principal Investigator: Veena Shankaran
Study Number: 20101327
Phase: III

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

[Complete title: A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin’s Lymphoma (NHL)]
Principal Investigator: Ajay Gopal, MD
Study Number: 20110654
Phase: I

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

[Complete title: A phase 2 study of brentuximab vedotin in relapsed or refractory CD30-positive non-Hodgkin lymphoma (NHL)]
Principal Investigator: Andrei Shustov, MD
Study Number: 20110853
Phase: II

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer (ONTRAC)

[Complete title: A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer]
Principal Investigator: Andrew Coveler, MD
Study Number: 20111067
Phase: III

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

[Complete title: A Phase 1b/2 Study with Gemcitabine and LY2157299 for Patients with Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)]
Principal Investigator: Andrew Coveler, MD
Study Number: 20111239
Phase: I/II

Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

[Complete title: Gilead GS-US-295-0203: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS or BRAF Mutant Colorectal Adenocarcinoma that Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen]
Principal Investigator: Andrew Coveler, MD
Study Number: 20111441
Phase: II

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)

[Complete title: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma]
Principal Investigator: Maciej Mrugala, MD, PhD
Study Number: 20111531
Phase: III

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

[Complete title: A Phase III Clinical Trial of Intra-arterial TheraSphere in the Treatment of Patient with Unresectable Hepatocellular Carcinoma (HCC)]
Principal Investigator: William Harris
Study Number: 20111617
Phase: III

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (ReACT)

[Complete title: A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma]
Principal Investigator: Maciej Mrugala, MD, PhD
Study Number: 20111765
Phase: II

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

[Complete title: A Phase 1b, Open-label, Multicenter Study of BMS-936564 in Combination with Lenalidomide (Revlimid®) plus low-dose Dexamethasone, or with Bortezomib (Velcade®) plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20111816
Phase: I

A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations

[Complete title: A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects with Advanced Non-Small Cell Lung Cancer and BRAF Mutations]
Principal Investigator: Christina Baik
Study Number: 20111838
Phase: II

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

[Complete title: A Multi-arm Phase I Study of BMS-936558 in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, or Carboplatin/Paclitaxel in Subjects with Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)]
Principal Investigator: Laura Chow
Study Number: 20120011
Phase: I

Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy

[Complete title: POLARIS2009-001: A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy]
Principal Investigator: William Harris
Study Number: 20120106
Phase: III

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

[Complete title: A Phase 3 Randomized, Two-Arm, Open Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma]
Principal Investigator: Andrei Shustov, MD
Study Number: 20120291
Phase: III

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer (STRIVE)

[Complete title: STRIVE: A multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide vs Bicalutamide in Men with Prostate Cancer who have Failed Primary Androgen Deprivation Therapy]
Principal Investigator: Tia Higano, MD
Study Number: 20120956
Phase: II

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

[Complete title: A multi-arm dose-finding phase Ib multicenter study of imatinib in combination with the oral phosphatidyl-inositol 3-kinase (PI3-K) inhibitor BKM120 in patients with Gastrointestinal Stromal Tumor (GIST) who failed prior therapy with imatinib and sunitinib]
Principal Investigator: Robin Jones
Study Number: 20121008
Phase: I

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

[Complete title: A Phase 1, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP30862 in Patients with Metastatic Castration-Resistant Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 20121064
Phase: I

A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

[Complete title: A Phase I, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects with Renal Cell Carcinoma of Clear Cell or Papillary Histology]
Principal Investigator: John Thompson, MD
Study Number: 20121076
Phase: I

Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation. (SOURCE)

[Complete title: A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcoma]
Principal Investigator: Robin Jones
Study Number: 20121175
Phase: II

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

[Complete title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30-Positive Mature T-cell Lymphomas]
Principal Investigator: Andrei Shustov, MD
Study Number: 20121207
Phase: III

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

[Complete title: Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell LymphomaOpen-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma]
Principal Investigator: Andrei Shustov, MD
Study Number: 20121464
Phase: III

A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)

[Complete title: A PhaseI/IIa Study of Safety and Efficacy of Alpharadin® with Docetaxel in Patients with Bone Metastases from Castration-Resistant Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 20121484
Phase: I/II

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

[Complete title: An International Phase 3, Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT).]
Principal Investigator: Scott Tykodi, MD
Study Number: 20121579
Phase: III

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

[Complete title: A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 20121654
Phase: I/II

A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

[Complete title: Armor2: A Phase 2 Trial, Randomized Two Part Study Of Galeterone In The Treatment Of Castration Resistant Prostate Cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 20121824
Phase: II

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

[Complete title: A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects with Solid Tumors]
Principal Investigator: Elizabeth Swisher, MD
Study Number: 20121952
Phase: I

Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer

[Complete title: A phase I/II, multicenter, open-label dose finding study of oral CFG920 in patients with metastatic castration-resistant prostate cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 20122057
Phase: I/II

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy

[Complete title: A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy]
Principal Investigator: William Harris
Study Number: 20122073
Phase: III

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

[Complete title: Phase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with metastatic castration resistant prostate cancer maintained on androgen deprivation therapy.]
Principal Investigator: Evan Yu, MD
Study Number: 20122140
Phase: II

A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

[Complete title: An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects with Refractory Follicular Lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 20130076
Phase: II

STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer

[Complete title: Steam (Sequencing Triplet with Avastin and Maintenance): Folfoxiri/Bevacizumab Regimens (Concurrent and Sequential) vs. Folfox/Bevacizumab in First-Line Metastatic Colorectal Cancer]
Principal Investigator: Gabriela Chiorean
Study Number: 20130142
Phase: II

A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.

[Complete title: COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection]
Principal Investigator: Kim Margolin, MD
Study Number: 20130566
Phase: III

A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - "FIR"

[Complete title: A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer]
Principal Investigator: Laura Chow
Study Number: 20130654
Phase: II

Study of MK-3475 in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)

[Complete title: A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors]
Principal Investigator: Laura Chow
Study Number: 20130878
Phase: I

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

[Complete title: The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 20130917
Phase: II

A Phase 1 Study of LY2787106 in Cancer and Anemia

[Complete title: A Phase 1 Safety Study of LY2787106 in Patients with Cancer and Anemia]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20130992
Phase: I

A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma

[Complete title: An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma]
Principal Investigator: Marc Chamberlain, MD
Study Number: 20131088
Phase: I/II

AZD8186 First Time In Patient Ascending Dose Study

[Complete title: A Phase 1, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZ8186 in Patients with Advanced Castrate-resistant Prostate Cancer (CRPC), Squamoous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-Deficient Advance Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZ8186 with Prospectively-validated PTEN-deficient Tumors]
Principal Investigator: Tia Higano, MD
Study Number: 20131275
Phase: I

Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer

[Complete title: Phase 2 Study of SPI-1620 in Combination with Docetaxel as a Second-Line Treatment for Patients with Advanced Biliary Cancer]
Principal Investigator: Gabriela Chiorean
Study Number: 20131451
Phase: II

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

[Complete title: An open-label, multicenter, randomized, Phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine + RO5072759 (GA101) in patients with rituximab-refractory, indolent non-Hodgkin’s lymphoma]
Principal Investigator: Oliver Press, MD, PhD
Study Number: 2388.00
Phase: III

A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease

[Complete title: An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman’s Disease]
Principal Investigator: Corey Casper
Study Number: 2502.00
Phase: II

A Safety Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

[Complete title: A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carflizomib and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2512.00
Phase: I

Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

[Complete title: A Phase I Clinical Study of CWP232291 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia-2 (CMML-2), Myelodysplasic Syndrome Having Failed Hypomethylating Treatment (MDS) and High-Risk Myelofibrosis (MF)]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2513.00
Phase: I

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma

[Complete title: A Phase 1 Study Evaluating the Safety, Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2515.00
Phase: I

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

[Complete title: A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone with or without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2521.00
Phase: III

Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

[Complete title: Head to Head Trial of Ofatumumab versus Rituximab – A Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy]
Principal Investigator: Benjamin Greer, MD
Study Number: 2522.00
Phase: III

tudy of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

[Complete title: A randomized, prospective, double blind, placebocontrolled, phase 3 study of US-ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GVHD in adult acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors]
Principal Investigator: Paul Martin, MD
Study Number: 2523.00
Phase: III

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

[Complete title: A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults with Relapsed or Refractory Flt3-ITD positive Acute Myeloid Leukemia]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2532.00
Phase: I/II

Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patient

[Complete title: A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2572.00
Phase: I/II

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

[Complete title: A Phase 1b Study to Evaluate the Safety and Preliminary Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose Ara-C or Decitabine in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (WIRB 20120285, Study 1132239)]
Principal Investigator: Vivian Oehler, MD
Study Number: 2592.00
Phase: I/II

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM3)

[Complete title: A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy]
Principal Investigator: Michael Boeckh, MD
Study Number: 2593.00
Phase: III

A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)

[Complete title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2597.00
Phase: III

Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma (11-MM-01)

[Complete title: A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone Prior to Autologous Stem Cell Transplant in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2599.00
Phase: I

Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116

[Complete title: A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS-1101 (CAL-101) as Therapy for Patients with Previously Treated Chronic Lymphocytic Leukemia]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2613.00
Phase: III

A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission

[Complete title: A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse]
Principal Investigator: Roland Walter, MD
Study Number: 2616.00
Phase: I

tudy to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

[Complete title: Phase III Randomized Observer –Blind Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals’ Herpes Zoster Vaccine GSK1437173A]
Principal Investigator: Michael Boeckh, MD
Study Number: 2635.00
Phase: III

A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma

[Complete title: A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DCDT2980S in Combination with Rituximab or DCDS4501A in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma]
Principal Investigator: Oliver Press, MD, PhD
Study Number: 2649.00
Phase: II

Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia (301)

[Complete title: Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 years of Age with Untreated High Risk (secondary) AML]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2651.00
Phase: III

ety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

[Complete title: A Phase1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2653.00
Phase: I

Early Diagnosis of Pulmonary Nodules

[Complete title: Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier]
Principal Investigator: David Madtes, MD
Study Number: 2658.00
Phase: NA

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma

[Complete title: A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory B Cell Malignancies]
Principal Investigator: Bill Bensinger, MD
Study Number: 2669.00
Phase: I/II

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

[Complete title: A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Subjects with Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes]
Principal Investigator: Bart Scott, MD
Study Number: 2685.00
Phase: III

A Safety Study of SGN-CD33A in AML Patients

[Complete title: A Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia]
Principal Investigator: Roland Walter, MD
Study Number: 2690.00
Phase: I

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

[Complete title: A Multicenter Phase 2 Study of the Bruton’s Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2694.00
Phase: II

An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

[Complete title: An Open-Label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 versus Chlorambucil)]
Principal Investigator: John Pagel, MD, PhD
Study Number: 2717.00
Phase: III

Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

[Complete title: Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Combination with Lenalidomide or Oral Cyclophosphamide in Patients with Newly Diagnosed Multiple Myeloma]
Principal Investigator: Bill Bensinger, MD
Study Number: 2723.00
Phase: I/II

Dose Escalation Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

[Complete title: A Phase 1 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal antibody (SAR650984) Against CD38 in Patients with Selected CD38+ Hematological Malignancies]
Principal Investigator: Bill Bensinger, MD
Study Number: 2724.00
Phase: I

Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer

[Complete title: A Phase II Study of Intratumoral Injection of Interleukin-12 Plasmid and in Vivo Electroporation in Patients With Merkel Cell Carcinoma]
Principal Investigator: Shailender Bhatia, MD
Study Number: 7248
Phase: II

Immunotherapy Study for Surgically Resected Pancreatic Cancer

[Complete title: A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute ® Pancreas (Algenpantucel-L) Immunotherapy in Subjects with Surgically Resected Pancreatic Cancer]
Principal Investigator: Andrew Coveler, MD
Study Number: 7259
Phase: III

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (EPOCH)

[Complete title: A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy]
Principal Investigator: William Harris
Study Number: 7627
Phase: III

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma (RELEVANCE)

[Complete title: A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus chemotherapy Followed by Rituximab in subjects with Previously Untreated Follicular Lymphoma (The “RELEVANCE” Trial)]
Principal Investigator: Edward Libby
Study Number: 7636
Phase: III

Trial of pIL-12 Electroporation Malignant Melanoma (IL12MEL)

[Complete title: A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Advanced Stage Cutaneous and in Transit Malignant Melanoma]
Principal Investigator: Shailender Bhatia, MD
Study Number: 7703
Phase: II

Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

[Complete title: A Phase 3, open-label, multicenter, randomized study of sequential Zevalin (ibritumomab tiuxetan) versus observation in patients at least 60 years of age with newly diagnosed diffuse large B-cell lymphoma in PET-negative complete remission after R-CHOP or R-CHOP-like therapy]
Principal Investigator: Ajay Gopal, MD
Study Number: 7779
Phase: III

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (PILLAR)

[Complete title: A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute - Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer]
Principal Investigator: Andrew Coveler, MD
Study Number: 8028
Phase: III

Search Options

Select a disease from the list below:
Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:
Limit results to studies enrolling:

OR

View all studies
Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.